Brain metastases at the time of the diagnostic stage and the initial treatment response to afatinib are two important prognostic factors for the overall survival of first-line afatinib treated EGFR mutation-positive lung adenocarcinoma. Here, EGFR is linked to lung adenocarcinoma.